Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have earned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $11.13.

A number of research firms recently weighed in on STRO. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Sutro Biopharma in a report on Monday, November 18th. Wells Fargo & Company dropped their price objective on shares of Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. JMP Securities reaffirmed a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a report on Wednesday, December 11th. Finally, Wedbush reissued an “outperform” rating and issued a $8.00 price target on shares of Sutro Biopharma in a report on Tuesday, December 10th.

Sutro Biopharma Stock Up 2.9 %

Shares of NASDAQ STRO opened at $1.79 on Tuesday. The business’s 50 day moving average price is $1.96 and its two-hundred day moving average price is $3.08. The company has a market cap of $147.60 million, a PE ratio of -1.11 and a beta of 1.15. Sutro Biopharma has a twelve month low of $1.51 and a twelve month high of $6.13.

Institutional Trading of Sutro Biopharma

A number of institutional investors have recently bought and sold shares of the business. Bank of Montreal Can acquired a new stake in shares of Sutro Biopharma in the third quarter valued at approximately $2,852,000. BNP Paribas Financial Markets raised its holdings in Sutro Biopharma by 1,195.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 82,524 shares of the company’s stock valued at $286,000 after acquiring an additional 76,152 shares in the last quarter. Barclays PLC lifted its position in shares of Sutro Biopharma by 385.3% during the 3rd quarter. Barclays PLC now owns 273,019 shares of the company’s stock valued at $944,000 after acquiring an additional 216,757 shares during the period. Jane Street Group LLC grew its holdings in shares of Sutro Biopharma by 30.7% during the 3rd quarter. Jane Street Group LLC now owns 108,192 shares of the company’s stock worth $374,000 after purchasing an additional 25,416 shares in the last quarter. Finally, State Street Corp increased its position in shares of Sutro Biopharma by 5.2% in the third quarter. State Street Corp now owns 1,647,162 shares of the company’s stock worth $5,699,000 after purchasing an additional 81,855 shares during the period. Institutional investors own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.